Novo Nordisk A/S (NVO)
47.51
+0.74
(+1.58%)
USD |
NYSE |
Sep 03, 16:00
46.54
-0.97
(-2.04%)
Pre-Market: 09:07
Novo Nordisk Cash from Investing (Quarterly) : -2.009B for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.009B |
| March 31, 2026 | -1.875B |
| December 31, 2025 | -6.527B |
| September 30, 2025 | -2.443B |
| June 30, 2025 | -2.105B |
| March 31, 2025 | -941.45M |
| December 31, 2024 | -13.35B |
| September 30, 2024 | -3.061B |
| June 30, 2024 | -3.007B |
| March 31, 2024 | 575.87M |
| December 31, 2023 | -2.136B |
| September 30, 2023 | -1.921B |
| June 30, 2023 | -1.354B |
| March 31, 2023 | -958.18M |
| December 31, 2022 | -1.931B |
| September 30, 2022 | -693.02M |
| June 30, 2022 | -609.07M |
| March 31, 2022 | -287.52M |
| December 31, 2021 | -3.251B |
| September 30, 2021 | -740.52M |
| June 30, 2021 | -467.94M |
| March 31, 2021 | -564.42M |
| December 31, 2020 | -1.996B |
| September 30, 2020 | -923.59M |
| June 30, 2020 | -201.93M |
| Date | Value |
|---|---|
| March 31, 2020 | -311.85M |
| December 31, 2019 | -474.68M |
| September 30, 2019 | -365.49M |
| June 30, 2019 | -426.10M |
| March 31, 2019 | -462.03M |
| December 31, 2018 | -634.60M |
| September 30, 2018 | -447.96M |
| June 30, 2018 | -406.04M |
| March 31, 2018 | -426.46M |
| December 31, 2017 | -489.43M |
| September 30, 2017 | -302.44M |
| June 30, 2017 | -107.25M |
| March 31, 2017 | -101.20M |
| December 31, 2016 | -402.28M |
| September 30, 2016 | -399.68M |
| June 30, 2016 | 30.28M |
| March 31, 2016 | -241.03M |
| December 31, 2015 | -694.94M |
| September 30, 2015 | -495.68M |
| June 30, 2015 | 6.051M |
| March 31, 2015 | 277.96M |
| December 31, 2014 | -278.72M |
| September 30, 2014 | -189.02M |
| June 30, 2014 | 24.09M |
| March 31, 2014 | 76.38M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AstraZeneca PLC | -1.856B |
| Johnson & Johnson | -1.11B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
| Novartis AG | -3.090B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 8.364B |
| Cash from Financing (Quarterly) | -2.708B |
| Free Cash Flow | 7.517B |
| Free Cash Flow Per Share (Quarterly) | 1.434 |
| Free Cash Flow to Equity (Quarterly) | 7.500B |
| Free Cash Flow to Firm (Quarterly) | 6.544B |
| Free Cash Flow Yield | 3.56% |